Answers are grounded in this paper and cite their sources.
Background & Aims Proteomic technology has been developed as a non-invasive test to grade and stage metabolic dysfunction-associated steatohepatitis (MASH). The aims of this post-hoc analysis of the STEP 1 and 2 trials were to assess the distribution of SomaSignal-derived MASH components and the effect of semaglutide (2.4 mg and 1.0 mg) treatment on MASH components assessed by SomaSignal proteomics, and to test for concordance with biopsy-based MASH histology from the phase 2b Sema-MASH trial. Methods Participants with overweight/obesity (STEP 1) and type 2 diabetes (STEP 2) receiving once-weekly semaglutide or placebo for 68 weeks and with biologic samples were included. Participants with biopsy-confirmed MASH (phase 2b MASH trial) receiving once-daily semaglutide or placebo for 72 weeks were also included in the analysis. Results SomaSignal-derived steatosis was highly prevalent in the STEP 1 and 2 trials (43.2% and 71.7%, respectively). The odds of having SomaSignal-defined MASH components at week 68 were significantly lower for participants who received semaglutide versus placebo. Participants receiving semaglutide were also likely to have a less severe SomaSignal-derived metabolic dysfunction-associated steatotic liver disease stage versus placebo at week 68; (odds ratio [95% CI]) for semaglutide 2.4 mg: STEP 1 (5.26 [3.59–7.72]); STEP 2 (4.90 [2.86–8.40]); p < 0.0001. MASH components were correlated with histologic change, simple liver-related biomarkers, and measures of glycemic control. Conclusions Our results suggest that the SomaSignal MASH components test may be useful to explore potential treatment effects of semaglutide among patients with related comorbidities; however, prospective, randomized clinical trials are needed for confirmation. Clinical trial registration numbers STEP 1: NCT03548935; STEP 2: NCT03552757; MASH phase 2b trial: NCT02970942 Impact and implications Liver biopsy is the current gold standard for diagnosis of metabolic dysfunction-associated steatohepatitis (MASH); however, this procedure is invasive and time consuming for patients living with MASH. The use of non-invasive tests to diagnose MASH is becoming increasingly popular and many clinicians see this approach as the diagnostic future. SomaSignal is a proteomics-based model designed to non-invasively test for and validate MASH components as well as detect the prevalence of metabolic dysfunction-associated steatotic liver disease stages, against biopsy results. In the future, SomaSignal MASH components may have an impact on future clinical practice by providing clinicians with an alternative option for non-invasive assessment of treatment effects in early clinical development of therapeutics.
No takes yet. Share an insight, caveat, or question.
Schattenberg et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: